Success Metrics

Active Trials
5(83%)

Phase Distribution

Ph phase_3
2
33%
Ph phase_2
2
33%
Ph phase_1
2
33%

Phase Distribution

2

Early Stage

2

Mid Stage

2

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
2(33.3%)
Phase 2Efficacy & side effects
2(33.3%)
Phase 3Large-scale testing
2(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

5

trials recruiting

Total Trials

6

all time

Status Distribution
Active(6)

Detailed Status

Recruiting4
Not yet recruiting1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
5
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 12 (33.3%)
Phase 22 (33.3%)
Phase 32 (33.3%)

Trials by Status

not_yet_recruiting117%
recruiting467%
active_not_recruiting117%

Recent Activity

5 active trials
Showing 5 of 6
not_yet_recruitingphase_1

A Study of Rocbrutinib Combined With R-GemOx in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

NCT07570017
recruitingphase_3

ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL

NCT07342478
recruitingphase_3

A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma

NCT07377578
active_not_recruitingphase_2

A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma

NCT05716087
recruitingphase_2

A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma

NCT07189065
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT07570017Phase 1

A Study of Rocbrutinib Combined With R-GemOx in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Not Yet Recruiting
NCT07342478Phase 3

ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL

Recruiting
NCT07377578Phase 3

A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma

Recruiting
NCT05716087Phase 2

A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma

Active Not Recruiting
NCT07189065Phase 2

A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma

Recruiting
NCT06251180Phase 1

Phase Ib Study of Rocbrutinib in Combination with R-CHOP in Patients with Newly Diagnosed B-cell Non-Hodgkin Lymphoma

Recruiting

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6